Columbano A, Ledda-Columbano G M, Pibiri M, Concas D, Reddy J K, Rao M S
Dipartimento di Tossicologia, Sezione di Oncologia e Patologia Molecolare, Università di Cagliari, Italy.
Hepatology. 2001 Aug;34(2):262-6. doi: 10.1053/jhep.2001.26172.
Previously, we have suggested that liver cell proliferation induced by certain mitogens is dependent on their binding and activation of nuclear receptors of the steroid/thyroid superfamily. More recently, it was shown that absence of the nuclear receptors peroxisome proliferator-activated receptor-alpha (PPARalpha) and constitutive androstane receptor (CAR) completely abolishes the proliferative response of hepatocytes to the mitogenic stimulus exerted by their specific ligands, peroxisome proliferators (PPs) and 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), respectively. Here we show that deletion of the PPARalpha gene accelerates and enhances the proliferative response evoked by the xenobiotic 1,4-bis[2-(3,5-dichloropyridyloxy)] benzene (TCPOBOP), a powerful mouse-liver mitogen and a ligand of the nuclear receptor CAR. Indeed, the number of hepatocytes entering S phase 24 hours after mitogen treatment was much greater in PPARalpha(-/-) mice compared with that of wild type mice (labeling indices 21.4% and 7.5%, respectively). Labeling index of hepatocytes from PPARalpha(-/-) mice was found to be higher than that of wild type mice up to 36 hours after treatment, indicating that lack of PPARalpha not only accelerated but also enhanced the overall proliferative response of the liver. The accelerated entry into S phase observed in hepatocytes from PPARalpha(-/-) mice was associated with a very rapid induction of cyclin D1. No major differences between TCPOBOP-treated PPARalpha(-/-) and wild type mice were observed in the expression of the 2 inhibitors of cyclin/CDKs complexes, p27 and p21. The results suggest that PPARalpha may play a role in modulating CAR-signaling pathways in the cell, in particular those leading to hepatocyte proliferation.
此前,我们曾提出某些促有丝分裂原诱导的肝细胞增殖依赖于它们与类固醇/甲状腺超家族核受体的结合及激活。最近有研究表明,核受体过氧化物酶体增殖物激活受体α(PPARα)和组成型雄甾烷受体(CAR)的缺失会完全消除肝细胞对其特定配体过氧化物酶体增殖物(PPs)和1,4-双[2-(3,5-二氯吡啶氧基)]苯(TCPOBOP)所施加的促有丝分裂刺激的增殖反应。在此我们发现,PPARα基因的缺失会加速并增强由外源性物质1,4-双[2-(3,5-二氯吡啶氧基)]苯(TCPOBOP)引发的增殖反应,TCPOBOP是一种强效的小鼠肝脏促有丝分裂原及核受体CAR的配体。实际上,与野生型小鼠相比,PPARα(-/-)小鼠在促有丝分裂原处理24小时后进入S期的肝细胞数量要多得多(标记指数分别为21.4%和7.5%)。在处理后长达36小时内,发现PPARα(-/-)小鼠肝细胞的标记指数高于野生型小鼠,这表明PPARα的缺失不仅加速了肝脏的整体增殖反应,还增强了该反应。在PPARα(-/-)小鼠肝细胞中观察到的加速进入S期与细胞周期蛋白D1的快速诱导有关。在细胞周期蛋白/细胞周期蛋白依赖性激酶(CDK)复合物的两种抑制剂p27和p21的表达方面,未观察到经TCPOBOP处理的PPARα(-/-)小鼠与野生型小鼠之间存在重大差异。这些结果表明,PPARα可能在调节细胞内CAR信号通路中发挥作用,特别是那些导致肝细胞增殖的信号通路。